A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy

DOI: 10.1212/wnl.0000000000004570
Neurology, 2017, 89, 1811-1820.

#	Paper	IF	Citations
54	Neuromuscular disease: Tadalafil fails to halt the progression of Duchenne muscular dystrophy. *Nature Reviews Neurology*, **2017**, 13, 707	15	1
53	Employment of Microencapsulated Sertoli Cells as a New Tool to Treat Duchenne Muscular Dystrophy. *Journal of Functional Morphology and Kinesiology*, **2017**, 2, 47	2.4	3
52	Duchenne muscular dystrophy: genome editing gives new hope for treatment. *Postgraduate Medical Journal*, **2018**, 94, 296-304	2	2
51	Neurology Care, Diagnostics, and Emerging Therapies of the Patient With Duchenne Muscular Dystrophy. *Pediatrics*, **2018**, 142, S5-S16	7.4	13
50	Role of neuronal nitric oxide synthase (nNOS) in Duchenne and Becker muscular dystrophies - Still a possible treatment modality?. *Neuromuscular Disorders*, **2018**, 28, 914-926	2.9	16
49	Targeting the Muscle-Bone Unit: Filling Two Needs with One Deed in the Treatment of Duchenne Muscular Dystrophy. *Current Osteoporosis Reports*, **2018**, 16, 541-553	5.4	9
48	Timed function tests have withstood the test of time as clinically meaningful and responsive endpoints in duchenne muscular dystrophy. *Muscle and Nerve*, **2018**, 58, 614-617	3.4	3
47	Nutrition in Duchenne muscular dystrophy 16-18 March 2018, Zaandam, the Netherlands. *Neuromuscular Disorders*, **2018**, 28, 680-689	2.9	6
46	Therapeutic targeting of 3ţ5ŧcyclic nucleotide phosphodiesterases: inhibition and beyond. *Nature Reviews Drug Discovery*, **2019**, 18, 770-796	64.1	100
45	Membrane recruitment of nNOSμ in microdystrophin gene transfer to enhance durability. *Neuromuscular Disorders*, **2019**, 29, 735-741	2.9	1
44	Duchenne muscular dystrophy: an historical treatment review. *Arquivos De Neuro-Psiquiatria*, **2019**, 77, 579-589	1.6	15
43	Cardiac and skeletal muscle effects in the randomized HOPE-Duchenne trial. *Neurology*, **2019**, 92, e866-e878	6.3	43
42	Therapeutic developments for Duchenne muscular dystrophy. *Nature Reviews Neurology*, **2019**, 15, 373-386	15	140
41	Advancements in magnetic resonance imaging-based biomarkers for muscular dystrophy. *Muscle and Nerve*, **2019**, 60, 347-360	3.4	6
40	Do porcine Sertoli cells represent an opportunity for Duchenne muscular dystrophy?. *Cell Proliferation*, **2019**, 52, e12599	7.9	5
39	Effects of PDE5 inhibition on dystrophic muscle following an acute bout of downhill running and endurance training. *Journal of Applied Physiology*, **2019**, 126, 1737-1745	3.7	7
38	Teaching an Old Molecule New Tricks: Drug Repositioning for Duchenne Muscular Dystrophy. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	6

37	Ronald G. Victor. *Hypertension*, **2019**, 73, 13-14	8.5	
36	Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials. *Muscle and Nerve*, **2020**, 61, 26-35	3.4	21
35	Intramuscular blood flow in Duchenne and Becker Muscular Dystrophy: Quantitative power Doppler sonography relates to disease severity. *Clinical Neurophysiology*, **2020**, 131, 1-5	4.3	5
34	Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: past, present, and future. *Pharmacological Reports*, **2020**, 72, 1227-1263	3.9	19
33	Nitric Oxide (NO) and Duchenne Muscular Dystrophy: NO Way to Go?. *Antioxidants*, **2020**, 9,	7.1	5
32	Update on Muscular Dystrophies with Focus on Novel Treatments and Biomarkers. *Current Neurology and Neuroscience Reports*, **2020**, 20, 14	6.6	6
31	Is Exercise-Induced Fatigue a Problem in Children with Duchenne Muscular Dystrophy?. *Neuropediatrics*, **2020**, 51, 342-348	1.6	1
30	Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: A multi-institutional collaboration. *PLoS ONE*, **2020**, 15, e0232870	3.7	6
29	Walking and weakness in children: a narrative review of gait and functional ambulation in paediatric neuromuscular disease. *Journal of Foot and Ankle Research*, **2020**, 13, 10	3.2	11
28	Suitability of external controls for drug evaluation in Duchenne muscular dystrophy. *Neurology*, **2020**, 95, e1381-e1391	6.5	12
27	Diagnostic differences in respiratory breathing patterns and work of breathing indices in children with Duchenne muscular dystrophy. *PLoS ONE*, **2020**, 15, e0226980	3.7	6
26	PDE10A Inhibition Reduces the Manifestation of Pathology in DMD Zebrafish and Represses the Genetic Modifier PITPNA. *Molecular Therapy*, **2021**, 29, 1086-1101	11.7	4
25	Soluble guanylate cyclase stimulation mitigates skeletal and cardiac muscle dysfunction in a mdx model of Duchenne muscular dystrophy.		0
24	Recent advances of glucocorticoids in the treatment of Duchenne muscular dystrophy (Review). *Experimental and Therapeutic Medicine*, **2021**, 21, 447	2.1	4
23	Cardioprotective Effect of Whole Body Periodic Acceleration in Dystrophic Phenotype Rodent. *Frontiers in Physiology*, **2021**, 12, 658042	4.6	2
22	Bayesian adaptive design for clinical trials in Duchenne muscular dystrophy. *Statistics in Medicine*, **2021**, 40, 4167-4184	2.3	3
21	Assessing the Use of the sGC Stimulator BAY-747, as a Potential Treatment for Duchenne Muscular Dystrophy. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	0
20	Clinical outcome assessments in Duchenne muscular dystrophy and spinal muscular atrophy: past, present and future. *Neuromuscular Disorders*, **2021**, 31, 1028-1037	2.9	0

19	Current Pharmacological Strategies for Duchenne Muscular Dystrophy. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 689533	5.7	4
18	Effect of Tadalafil Administration on Redox Homeostasis and Polyamine Levels in Healthy Men with High Level of Physical Activity. *International Journal of Environmental Research and Public Health*, **2021**, 18,	4.6	0
17	Cross-section and feasibility study on the non-invasive evaluation of muscle hemodynamic responses in Duchenne muscular dystrophy by using a near-infrared diffuse optical technique. *Biomedical Optics Express*, **2018**, 9, 4767-4780	3.5	4
16	Meta-analyses of deflazacort versus prednisone/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy. *Journal of Comparative Effectiveness Research*, **2021**, 10, 1337-1347	2.1	1
15	The root cause of Duchenne muscular dystrophy is the lack of dystrophin in smooth muscle of blood vessels rather than in skeletal muscle per se. *F1000Research*, 7, 1321	3.6	1
14	Dystrophinopathies. **2020**, 413-436		
13	Funcionalidade de membro superior em pacientes deambuladores e nã deambuladores com distrofia muscular de Duchenne. *Fisioterapia E Pesquisa*, **2020**, 27, 188-193	0.2	1
12	Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy. *Frontiers in Pharmacology*, **2021**, 12, 735912	5.6	0
11	Efficacy and safety of glucocorticoids in the treatment of progressive muscular dystrophy in children: a systematic review and meta-analysis.. *Translational Pediatrics*, **2021**, 10, 3046-3057	4.2	
10	Physiologically based pharmacokinetic modeling of tadalafil to inform pediatric dose selection in children with pulmonary arterial hypertension. *CPT: Pharmacometrics and Systems Pharmacology*, **2021**,	4.5	1
9	Therapeutic approaches to preserve the musculature in Duchenne Muscular Dystrophy: The importance of the secondary therapies. *Experimental Cell Research*, **2021**, 410, 112968	4.2	4
8	Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls.. *Neuromuscular Disorders*, **2022**,	2.9	1
7	CRISPR-mediated correction of skeletal muscle Ca2+ handling in a novel DMD patient-derived pluripotent stem cell model.		
6	Emerging therapies for Duchenne muscular dystrophy. *Lancet Neurology, The*, **2022**,	24.1	4
5	Drug development progress in duchenne muscular dystrophy. *Frontiers in Pharmacology*, 13,	5.6	1
4	Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders. **2023**, 63,		1
3	Heart-on-a-chip platforms and biosensor integration for disease modeling and phenotypic drug screening. **2022**, 114840		1
2	CRISPR-mediated correction of skeletal muscle Ca2+ handling in a novel DMD patient-derived pluripotent stem cell model. **2022**,		0

1	Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status.	0